No buy transactions available for this period
No sell transactions available for this period
Gilead Sciences, Inc. filed its 13F report for Q1 2026 on May 08, 2026. The portfolio totaled 2.12 B reflecting a +9.42% change from the prior quarter, spanning 6 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. No significant position changes were reported during the quarter.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Gilead Sciences submitted their Form 13F-HR for the Q1 2026 period on 05/08/2026. This was the only submission for the quarter.
In the Q1 2026 filing, Gilead Sciences reported a managed portfolio value of 2.12 B, consisting of 6 individual positions.
This page displays the raw filing documents. To see which stocks Gilead Sciences bought or sold during Q1 2026, please visit Gilead Sciences's Portfolio Analysis page.